Post-Doctoral Position (PFCD- Peripheral Neuropathic pain team, NeuroDol Institute, Clermont-Ferrand, France, 2 years renewable)

Starting date: 01/10/2023


The NeuroDol institute located in Clermont-Ferrand (FRANCE) is one of the main public centres for both fundamental and clinic research in chronic pain and offers a state-of-the-art field of research.

Our lab provides a stimulating and scientifically rigorous environment for scientific growth and fostering the independent careers of postdoctoral trainees. Indeed, a large number of approaches are available within the unit, which include ex vivo brain slices, up to the in vivo preparations and freely moving animals. Analysis methods include cellular imaging, ex vivo and in vitro electrophysiology, microdialysis, neuromediator and drug assays, and functional neuroanatomy.

In addition, the campus provides a multidisciplinary research environment notably with the presence of the Cell Imaging Center for Health Research providing us with electronic and confocal microscopies, laser microdissection and flow cytometry as well as access to different experimental approaches through our labs, departments and core facilities to ensure the successful development of the research.

Within the team, our research focuses mainly on dissecting the mechanisms that lead to pain development and chronicization with a specific focus on chemotherapy-induced neuropathic pain (CIPN) and specific ion channels including K2P and HCN.


The position is available from October 1st, 2023. Initial funding for 24 months is available. Candidates are expected to have a competitive track record to apply for external follow-up funding.


We are looking for a candidate who possesses:

  1. A PhD degree with a background in cell biology in the field of cancer and/or neurobiology.
  2. Solid experimental skills, notably expertise in hiPS culture and differentiation towards neuronal lignages.
  3. Significant technical expertise in live cell/high resolution imaging, and in functional techniques (Ca2+-imaging, patch-clamp, MEA).

The ideal candidate should have excellent organisational skills, be highly motivated, creative and enthusiastic.

How to apply?

Candidates should send their CV including research interests and contact details of two referees in a single PDF file to

Useful links

Some selected publications from the team:

Selvy M., Mattévi C., Dalbos C., Aissouni Y., Chapuy E., Martin P-Y., Collin A., Richard D., Dumontet C., Busserolles J., Condé S., Balayssac D. Analgesic and preventive effects of donepezil in animal models of chemotherapy-induced peripheral neuropathy: involvement of spinal muscarinic acetylcholine M2 receptors. Biomedicine & Pharmacotherapy, 2022; 149 : 112915 doi: 10.1016/j.biopha.2022.112915.

Lamoine S., Cuménal M., Barriere D.A., Pereira V., Fereyrolles M., Prival L., Barbier J., Boudieu L., Brasset E., Bertin B., Renaud Y., Miot-Noirault E., Civiale M.A., Balayssac D., Aissouni Y., Eschalier A., Busserolles J. The class I HDAC inhibitor, MS-275, prevents oxaliplatin-induced chronic neuropathy and potentiates its antiproliferative activity in mice. Int. J. Molecular Sciences, 2021;23(1):98. doi: 10.3390/ijms23010098.

Busserolles J., Soussia I.B., Pouchol L., Marie N., Meleine M., Devilliers M., Judon C., Schopp J., Clémenceau L., Poupon L., Chapuy E., Noble F., Lesage F., Ducki S., Eschalier A., Lolignier S. TREK-1 channel activation as a new analgesic strategy devoid of opioid adverse effects. Brit J Pharmacol, 2020; doi: 10.1111/bph.15243.

Busserolles J., Lolignier S., Kerckhove N., Authier N., Eschalier A. Replacement of current opioid drugs focusing on MOR- related strategies. Pharmacol Ther., 2020; doi: 10.1016/J.pharmther.2020.107519 (invited review)

Poupon L., Lamoine S., Pereira V., Barriere D.A., Lolignier S., Giraudet F., Aissouni Y., Meleine M., Prival L., Richard D., Kerckhove N., Authier N., Balayssac D., Eschalier A., Lazdunski M., Busserolles J. Targeting the TREK-1 potassium channe via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin. Neuropharmacology, 2018; doi: 10.1016/j.neuropharm.2018.07.026.

Devilliers M., Busserolles J., Lolignier S., Deval E., Pereira V., Alloui A., Christin M., Mazet B., Delmas P., Noel J., Lazdunski M. and Eschalier A. Activation of TreK-1 by morphine results in analgesia without adverse side-effects. Nat. Commun. 2013;4:2941. doi: 10.1038/ncomms3941.

Descoeur J., Pereira V., Pizzoccaro A., Francois A., Ling B., Maffre V., Couette B., Busserolles J., Courteix C., Noel J., Lazdunski M., Eschalier A., Authier N., Bourinet E. Oxaliplatin-induced cold hypersensitivity is due to remodeling of ion channel expression in nociceptors. Embo Mol. Med., 2011;3(5):266-278. doi: 10.1002/emmm.201100134.